摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-methyl-4-(4-nitrophenyl)-1H-imidazole | 103298-41-5

中文名称
——
中文别名
——
英文名称
1-methyl-4-(4-nitrophenyl)-1H-imidazole
英文别名
1-methyl-4-(4-nitrophenyl)imidazole
1-methyl-4-(4-nitrophenyl)-1H-imidazole化学式
CAS
103298-41-5
化学式
C10H9N3O2
mdl
——
分子量
203.2
InChiKey
FYIKPTWCPQLHFV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    195 °C
  • 沸点:
    436.4±20.0 °C(Predicted)
  • 密度:
    1.29±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    63.6
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-methyl-4-(4-nitrophenyl)-1H-imidazole 以 MeOH on palladium 、 甲烷 为溶剂, 以93%的产率得到1-methyl-4-(4-aminophenyl)1H-imidazole
    参考文献:
    名称:
    Indolinones having kinase-inhibiting activity
    摘要:
    本发明涉及一般式##STR1##中R.sub.1至R.sub.3的定义如权利要求1所述,其异构体和盐,特别是具有有价值的药理特性的生理上可接受的盐,特别是对各种激酶和cycline/CDK复合物以及各种肿瘤细胞增殖具有抑制作用的盐,含有这些化合物的药物组合物,它们的用途和制备它们的方法。
    公开号:
    US06043254A1
  • 作为产物:
    描述:
    4-苯基咪唑硫酸硝酸 、 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.75h, 生成 1-methyl-4-(4-nitrophenyl)-1H-imidazole
    参考文献:
    名称:
    [EN] HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES
    [FR] INHIBITEURS DE BIOSYNTHÈSE D'HÉPARANE SULFATE POUR TRAITER DES MALADIES
    摘要:
    公开号:
    WO2016057834A9
点击查看最新优质反应信息

文献信息

  • Novel synthesis of 4(5)-monosubstituted imidazoles via cycloaddition of tosylmethyl isocyanide to aldimines
    作者:Ronald ten Have、Marco Huisman、Auke Meetsma、Albert M van Leusen
    DOI:10.1016/s0040-4020(97)00717-5
    日期:1997.8
    4(5)-Monosubstituted imidazoles (9) have been prepared via base-induced cycloaddition of tosylmethyl isocyanide (TosMIC) to N-(dimethylsulfamoyl)aldimines (2) or N-tosylaldimines (3). In the first case, N-(dimethylsulfamoyl)imidazoles 8 are the initial reaction products, from which the dimethylsulfamoyl group is readily removed with aqueous HBr. In the second case, the tosyl group of 1-tosylimidazoles
    4(5)-单取代的咪唑(9)是通过将甲苯磺酰基甲基异化物(TosMIC)与N-(二甲基磺酰基)醛亚胺(2)或N-甲苯磺酰基亚胺(3)进行碱诱导的环加成而制备的。在第一种情况下,N-(二甲基磺酰基)咪唑8是初始反应产物,可以用HBr溶液很容易地从中除去二甲基磺酰基。在第二种情况下,在一个操作中,1-甲苯咪唑10的甲苯磺酰基自发地丢失,得到4(5)-单取代的咪唑9。
  • Novel amide compounds
    申请人:——
    公开号:US20040087798A1
    公开(公告)日:2004-05-06
    A compound of the formula (I): R 1 -A-X-NHCO—Y—R 2 wherein R 1 is heterocyclic group which may have suitable substituents, or phenyl which may have suitable substituents, R 2 is condensed phenyl which may have suitable substituents, phenyl which may have suitable substituents, or thienyl which may have suitable substituents, A is a group of the formula: —(CH 2 ) t —(O) m — or 1 which R 3 and R 4 are each hydrogen or linked together to form imino, R 5 is hydrogen or lower alkyl, t is 0, 1 or 2, p, m and n are each 0 or 1, X is phenylene which may have suitable substituents, or bivalent heterocyclic group containing nitrogen which may have suitable substituents, Y is bond, lower alkylene, or lower alkenylene, and a salt thereof.
    化合物的结构式(I):R1-A-X-NHCO-Y-R2其中R1是杂环基团,可以有合适的取代基,或苯基,可以有合适的取代基,R2是紧缩苯基,可以有合适的取代基,苯基,可以有合适的取代基,或噻吩基,可以有合适的取代基,A是以下式子的基团:—(CH2)t—(O)m—或1其中R3和R4分别是氢或连接在一起形成亚胺,R5是氢或较低的烷基,t为0、1或2,p、m和n均为0或1,X是苯基,可以有合适的取代基,或含有氮的二价杂环基团,可以有合适的取代基,Y是键,较低的烷基,或较低的烯基,以及其盐。
  • Compounds for the treatment of inflammatory diseases
    申请人:Anderskewitz Ralf
    公开号:US20060258861A1
    公开(公告)日:2006-11-16
    Compounds of formula 1 and hetero derivatives thereof and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    化合物1及其杂环衍生物和其药学上可接受的盐、对映体、消旋体、合物或溶剂化物,适用于治疗呼吸或胃肠疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症,以及含有这些化合物的制药组合物。
  • Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
    申请人:Trieselmann Thomas
    公开号:US20080234278A1
    公开(公告)日:2008-09-25
    The present invention relates to new beta-agonists of general formula (I) wherein the groups R 1 to R 7 have the meanings given in the claims and specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, processes for preparing these compounds and their use as pharmaceutical compositions.
    本发明涉及通式(I)的新型β-激动剂,其中R1至R7的基团具有权利要求书和说明书中所给出的含义,它们的互变异构体、对映异构体、顺反异构体、混合物、前药及其盐,特别是与无机或有机酸或碱的生理上可接受的盐,制备这些化合物的过程以及它们作为药物组成物的用途。
  • NOVEL AMIDE COMPOUNDS
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP1264820A1
    公开(公告)日:2002-12-11
    A compound of the formula (I):         R1-A-X-NHCO-Y-R2    wherein R1 is heterocyclic group which may have suitable substituents, or phenyl which may have suitable substituents, R2 is condensed phenyl which may have suitable substituents, phenyl which may have suitable substituents, or thienyl which may have suitable substituents, A is a group of the formula:         -(CH2)t-(O)m- or in which R3 and R4 are each hydrogen or linked together to form imino, R5 is hydrogen or lower alkyl, t is 0, 1 or 2, p, m and n are each 0 or 1, X is phenylene which may have suitable substituents, or bivalent heterocyclic group containing nitrogen which may have suitable substituents, Y is bond, lower alkylene, or lower alkenylene, and a salt thereof.
    式 (I) 的化合物: R1-A-X-NHCO-Y-R2 其中 R1 是杂环基团,可带有合适的取代基,或苯基,可带有合适的取代基、 R2 是缩合苯基,可具有合适的取代基;苯基,可具有合适的取代基;或噻吩基,可 具有合适的取代基、 A 是式中的一个基团: -(CH2)t-(O)m- 或 其中 R3 和 R4 分别为氢或连接在一起形成亚基、 R5 是氢或低级烷基、 t 为 0、1 或 2、 p、m 和 n 均为 0 或 1、 X 是可以有适当取代基的亚苯基,或可以有适当取代基的含氮二价杂环基团、 Y 是键、低级亚烷基或低级亚烯基、 及其盐。
查看更多